FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 74 filers reported holding FATE THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $111,000 | -55.2% | 34,107 | -37.5% | 0.04% | -45.0% |
| Q1 2017 | $248,000 | +588.9% | 54,598 | +160.9% | 0.08% | +1042.9% |
| Q2 2016 | $36,000 | -67.3% | 20,925 | -35.6% | 0.01% | -41.7% |
| Q4 2015 | $110,000 | -83.0% | 32,495 | -73.2% | 0.01% | -80.6% |
| Q3 2015 | $646,000 | +22.1% | 121,151 | +48.1% | 0.06% | +19.2% |
| Q2 2015 | $529,000 | – | 81,797 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |